Healthcare / BiotechnologyNasdaqCM
$8.33
-0.79 (-8.66%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-16.2M · quality 66.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
33/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$10M
P/E
0.0x
↓EV/EBITDA
N/A
•ROE
-586.6%
↓Gross Margin
N/A
•Debt/Equity
0.20
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2010–2025 · 15 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.50x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-14.1M · FCF $-7.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||||
| Revenue | — | — | $582000.00 | $68000.00 | — | — | $5.8M | $19.8M | $23.3M | $21.3M | $22.3M | $24.5M | $26.0M | $23.7M | $24.1M | $23.9M | $25.3M |
| Net Income | $-14.1M | $-14.1M | $-44.5M | $-21.7M | $-24.6M | $-122.5M | $-7.3M | $-2.0M | $-259000.00 | $-1.1M | $-2.9M | $-7.2M | $-5.0M | $-1.1M | $-995000.00 | $-3.4M | $-400000.00 |
| EBITDA | $-13.8M | $-13.8M | $-36.1M | $-19.9M | $-24.0M | $-113.6M | $-7.2M | $1.1M | $3.0M | $915000.00 | $609000.00 | $-3.8M | $-2.0M | $1.7M | $1.8M | $-16000.00 | $2.9M |
| EPS | -56.00 | -56.00 | -1224.00 | -1530.00 | -3022.50 | -21228.75 | -3075.00 | — | — | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | 83.5% | -247.1% | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | -2963.9% | -30404.4% | — | — | -125.0% | -8.9% | 0.9% | -6.6% | -10.2% | -28.1% | -18.2% | -4.7% | -4.4% | -13.7% | -1.3% |
| Net Margin | — | — | -7652.7% | -31864.7% | — | — | -125.7% | -10.3% | -1.1% | -5.1% | -13.1% | -29.5% | -19.3% | -4.4% | -4.1% | -14.3% | -1.6% |
| Balance Sheet | |||||||||||||||||
| Debt/Equity | 0.20 | 0.20 | 0.40 | 18.74 | 0.10 | — | 0.07 | — | 0.54 | 0.93 | 1.99 | 1.93 | 0.49 | 0.17 | — | — | — |
| Current Ratio | 2.89 | 2.89 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||||
| Free Cash Flow | $-7.1M | $-7.1M | $-16.2M | $-20.4M | $-21.3M | $-23.6M | $-8.1M | $2.6M | $717000.00 | $-179000.00 | $-404000.00 | $-5.2M | — | — | $930000.00 | $-1.0M | $1.5M |
| Returns | |||||||||||||||||
| ROE | -586.6% | -586.6% | -2618.4% | -970.4% | -203.0% | -480.5% | -95.2% | -21.0% | -3.7% | -19.5% | -71.9% | -187.8% | -46.0% | -11.4% | -12.6% | -53.8% | -4.2% |
| Valuation | |||||||||||||||||
| P/E | 0.01 | 0.01 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 0.88 | 0.88 | 2.73 | 4.57 | 0.86 | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||||
| Revenue Growth | — | — | 755.9% | — | — | — | -70.7% | -15.1% | 9.7% | -4.7% | -9.0% | -5.9% | 9.7% | -1.3% | 0.8% | -5.7% | — |
| EPS Growth | 95.4% | 95.4% | 20.0% | 49.4% | — | -590.4% | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-89.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-1224.00 → -56.00
Residual
-89.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.